Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

FRX.TO Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Fennec Pharmaceuticals Inc.TSX: FRX.TO

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 35.55M shares rose 28.9% year over year, ahead of the +11.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 14.0% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +28.9% holds above the trailing-twelve-month pace of +11.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
35.55M+14.0% QoQ
Last fiscal yearDec 2025
28.58M+4.7% YoY
LTMMar 2026
30.57M+11.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.9%——
1 year+4.7%——
3-year CAGR+2.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
28.58M USD
Year-over-year change
+4.7%
4-year CAGR
+2.4%

Weighted Avg Shares (Diluted) vs competitors

How FRX.TO compares with its peers on the latest reported figures

  • FRX.TO's LTM Mar 2026 weighted avg shares (diluted) of 30.57M shares is the 7th highest of the 8 companies compared; the peer median is 75.7M shares.
  • Its year-over-year change of +11.5% is the 6th highest of 8, against a peer median of +21.4%.
  • Over three fiscal years its annual growth of +2.8% compares with a peer median of +10.8%.
FRX.TO Competitors Peer median
Weighted Avg Shares (Diluted) for FRX.TO and competitors
Company Period LTM YoY 3-year CAGR
TSND.TOTerrAscend Corp.LTM Mar 2026305.61M +4.7%+7.2%
WEED.TOCanopy Growth CorporationLTM Mar 2026288.35M +167.7%+8.4%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026134.1M +15.6%—
HBP.TOHelix BioPharma Corp.LTM Apr 202675.7M +289.1%+23.1%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 202645.37M +27.3%+27.5%
PRN.TOProfound Medical Corp.LTM Mar 202631.8M +21.4%+13.3%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 202630.57M +11.5%+2.8%
DR.TOMedical Facilities CorporationLTM Mar 202620.34M -14.4%-12.8%
Peer median (excluding FRX.TO) 75.7M+21.4%+10.8%

Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K254.38K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.04M32.76M41.79M47.22M
Depreciation & Amortization17.22M149K287K800K103K
EBITDA(17.19M)(22.74M)(12.65M)4.8M(7.45M)
EBITDA Margin—-1481.2%-59.5%10.1%-16.7%
Operating Income(17.22M)(22.59M)(12.77M)2.57M(6.35M)
Operating Margin—-1471.6%-60.1%5.4%-14.2%
Interest Income54K195K441K1.68M800.78K
Interest Expense126K978K3.39M4.07M2.18M
Other Income / Expenses(123K)(1.13M)(3.27M)(2.64M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense110K147K0365K106K
Net Income(17.46M)(23.86M)(16.05M)(436K)(9.74M)
Net Margin—-1554.5%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.91)(0.60)(0.02)(0.34)
EPS (Diluted)(0.67)(0.91)(0.60)(0.02)(0.34)
Weighted Avg Shares25.89M26.28M26.57M21.8M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.3M28.58M

Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$19.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.